Tyrosine kinase inhibitors differentially deregulate expression of metallothionein sub/isoforms in triple-negative breast cancer cells
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F62156489%3A43210%2F20%3A43919613" target="_blank" >RIV/62156489:43210/20:43919613 - isvavai.cz</a>
Result on the web
<a href="https://mnet.mendelu.cz/mendelnet2020/mnet_2020_full.pdf" target="_blank" >https://mnet.mendelu.cz/mendelnet2020/mnet_2020_full.pdf</a>
DOI - Digital Object Identifier
—
Alternative languages
Result language
angličtina
Original language name
Tyrosine kinase inhibitors differentially deregulate expression of metallothionein sub/isoforms in triple-negative breast cancer cells
Original language description
Metallothionein (MT) expression has been tied to drug resistance in cancer cells. The MT isoforms have also been investigated in connection to tyrosine kinase inhibitor (TKI) treatment - especially with sorafenib. Our work is focused on three different TKIs - vandetanib, lenvatinib and cabozantinib. Our aim was to investigate the effect of these TKIs on the expression of MT isoforms in breast cancer cell lines. We performed gene expression analysis of seven MT isoforms after TKI treatment. The analysis revealed that each TKI had a different impact on each cell line. Cabozantinib seemed to induce the biggest response of MT expression out of the three inhibitors, with fold change of MT1F and MT1G reaching 1.68 and 1.62, respectively, in MDA-MB-468 after 24h treatment. Lenvatinib, on the other hand, downregulated MT1X in the same cell line after 72h 0.48-fold. Similarly to MDA-MB-468, cabozantinib treatment upregulated MT1E and MT1X in MDA-MB-231 after 72h treatment, with 1.68 and 1.87-fold difference, respectively.
Czech name
—
Czech description
—
Classification
Type
D - Article in proceedings
CEP classification
—
OECD FORD branch
10608 - Biochemistry and molecular biology
Result continuities
Project
<a href="/en/project/GA18-10251S" target="_blank" >GA18-10251S: Comprehensive insight into mechanisms of action and metabolism of tyrosine kinase inhibitors and a study of ways increasing their antitumor efficiency</a><br>
Continuities
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)
Others
Publication year
2020
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Article name in the collection
MendelNet 2020: Proceedings of International PhD Students Conference
ISBN
978-80-7509-765-1
ISSN
—
e-ISSN
—
Number of pages
5
Pages from-to
562-566
Publisher name
Mendelova univerzita v Brně
Place of publication
Brno
Event location
Brno
Event date
Nov 11, 2020
Type of event by nationality
WRD - Celosvětová akce
UT code for WoS article
—